NEW YORK (GenomeWeb News) – IntelligentMDx today said that it has gained ISO certification from Canadian authorities to develop and manufacture its molecular diagnostic tests at its facilities in Cambridge , Mass., where the firm is based.

IMDx said that it underwent an audit of its quality system to ISO 13485:2003 with the implementation of requirements from the Canadian Medical Devices Regulations. The accreditation was received from the Laboratoire national de métrologie et d'essais and will enable the firm to seek licenses to commercialize its tests in Canada.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.